Delivery Order SPE2DB24D3013-SPE2DB25FFMMP

Award Date 6/13/25
Potential Completion Date 6/16/25
Potential Value $6.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $5,639.94 firm-fixed-price contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a diabetes treatment medication. The contract has a period of performance through June 10, 2025 and is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,102.24 firm fixed-price contract is for the delivery of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a diabetes medication. The award has a June 2025 completion date and is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $12,948.16 firm-fixed-price contract is for the supply of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml, a diabetes medication. The contract has an ultimate completion date of May 2, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA). The $8,003.82 firm-fixed-price delivery order is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a diabetes medication. The contract has an ultimate completion date of June 9, 2025 and is not set aside. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $10,706.61 firm fixed-price contract is for the delivery of Ozempic 2 mg/dose (8 mg/3 ml) 3 ml medication, with an ultimate completion date of May 21, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which...
This is a delivery order award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a diabetes medication. The award has a ceiling value of $22,462.76 and an ultimate completion date of January 16, 2025. It is a firm fixed-price contract with no set-aside designation. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This is a delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,932.90 firm fixed-price award is for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml, a diabetes medication. The contract has a period of performance through February 25, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,185.94 firm fixed-price contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a medication used for diabetes management. The award has an ultimate completion date of March 5, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The contract, valued at $41,768.23, is for the delivery of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a diabetes treatment medication. The contract is a firm fixed-price, non-set-aside delivery order with a completion date of May 13, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a delivery order with a firm fixed price of $19,162.28. The contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a diabetes medication, to the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of May 22, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
  • SPE2DB24D3013
    Indefinite Delivery Contract
  • SPE2DB24D3013-SPE2DB25FFMMP
    Delivery Order

This is a delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $6,778.06 firm fixed-price contract is for the delivery of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a diabetes medication. The order has an ultimate completion date of June 16, 2025.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00. This prime contract, designated as SPE2DX, provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. The IDC enables the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The contract award is not designated as a set-aside.

Generated 9/12/25, 10:49 AM